In a recent interview published in Best Health Canada magazine, Toronto brain surgeon Gelareh Zadeh discusses a new brain cancer therapy that could buy precious time for terminal patients.
Working with a colleague at the Princess Margaret Cancer Centre, she developed a blood test that can not only detect brain cancer but reveal the type of tumour and its likelihood to recur. And in a recent, groundbreaking clinical trial at the UHN, she helped identify a new combination therapy that may give patients with glioblastoma months or even years longer to live. In the interview, Zadeh discusses neurosurgery’s razor-thin margin of error, how to predict the risk for brain tumours and the value of staying in the moment.
Read the full interview in Best Health Canada magazine.
This research was published in the high impact journal Nature Medicine (Open Access)
Nassiri, F., Patil, V., Yefet, L.S. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 29, 1370–1378 (2023). https://doi.org/10.1038/s41591-023-02347-y
Visit the Zadeh lab website to learn more about her groundbreaking research.
Dr. Gelareh Zadeh is one of this year’s recipients of the 2023 Canada Gairdner Momentum Awards.
